| 李新军,马风妹,付丽梅,付明霞,吴 戈.EpCAM, Vimentin和N-Cadherin在三阴型乳腺癌中的表达和预后意义[J].现代生物医学进展英文版,2017,17(4):753-756. |
| EpCAM, Vimentin和N-Cadherin在三阴型乳腺癌中的表达和预后意义 |
| Expression and Prognostic Significance of EpCAM, Vimentin and N-Cadherin in Triple-negative Breast Cancer |
| Received:October 30, 2015 Revised:November 16, 2015 |
| DOI：10.13241/j.cnki.pmb.2017.04.040 |
| 中文关键词: 乳腺肿瘤 上皮细胞黏附分子 上皮-间质转化 免疫组织化学 |
| 英文关键词: Breast neoplasms Epithelial cell adhesion molecule Epithelial-mesenchymal transition Immunohistochemistry |
| 基金项目:山东省科技发展计划政策引导类项目（2013YD18032） |
|
| Hits: 382 |
| Download times: 258 |
| 中文摘要: |
| 摘要 目的：探讨EpCAM、Vimentin和N-Cadherin在三阴型乳腺癌（TNBC）中表达的临床病理及预后意义。方法：采用免疫组化MaxVisionTM法检测161 例TNBC中EpCAM、Vimentin和N-Cadherin表达，分析其与临床病理特征和预后的关系。结果： EpCAM、Vimentin及N-Cadherin在161 例TNBC中的表达率分别为62.1 %、20.5 %、17.4 %。EpCAM表达与Vimentin、N-Cadherin均具有正相关性。EpCAM和Vimentin蛋白阳性率均随着肿瘤体积增大、淋巴结阳性、TNM分期增高而增高（均为P＜0.05）；N-Cadherin表达率随着TNM分期增高而增高（P=0.000）。Log-rank检验和单因素分析显示，EpCAM、Vimentin和N-Cadherin阳性的患者预后较差（均为P＜0.001）。多因素COX分析显示，当仅经临床分期、肿瘤大小和淋巴结转移校正时，EpCAM是独立的预后因子（P=0.026），但纳入Vimentin和N-Cadherin后，EpCAM则不是独立的预后因子（P＞0.05）。结论：EpCAM在TNBC中与其临床病理特征和预后相关，并与EMT关系密切，EpCAM与EMT可能参与TNBC的发生发展过程。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinicopathological and prognostic significance of EpCAM，Vimentin and N-Cadherin expression in triple-negative breast cancer (TNBC). Methods: The expressions of EpCAM, Vimentin and N-Cadherin in 161 cases of TNBC were detected by immunohistochemical MaxVisionTM method, and the relationship between their expressions and the clinical pathological features and prognosis were analyzed. Results: The expression rates of EpCAM, Vimentin and N-Cadherin in 161 cases of TNBC were 62.1%, 20.5% and 17.4%, respectively. The expression of Vimentin was positively correlated with N-Cadherin and EpCAM. The positive rates of EpCAM and Vimentin increased with tumor size, lymph node positive and TNM stage (P < 0.05), and N-Cadherin expression increased with TNM stage (P=0.000). Log-rank test and univariate analysis showed that the expressions of EpCAM, Vimentin and N-Cadherin were associated with a significantly worse overall survival (P<0.001). In multivariate COX analysis, after adjusting for TNM stage, tumor size and lymph node metastasis, EpCAM was an independent prognostic factor (P=0.026), but it had no independent prognostic significance after adjusting for Vimentin and N-Cadherin further. Conclusion: EpCAM is associated with clinical- pathological features and prognosis in TNBC, and is closely related to EMT, EMT and EpCAM may be involved in the development of TNBC. |
|
View Full Text
View/Add Comment Download reader |
| Close |
